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Just as reference genome sequences revolutionized
human genetics, reference maps of interactome
networks will be critical to fully understand geno-
type-phenotype relationships. Here, we describe a
systematic map of 14,000 high-quality human bi-
nary protein-protein interactions. At equal quality,
this map is 30% larger than what is available from
small-scale studies published in the literature in the
last few decades. While currently available informa-
tion is highly biased and only covers a relatively small
portion of the proteome, our systematicmap appears
strikingly more homogeneous, revealing a ‘‘broader’’
human interactome network than currently appre-
ciated. The map also uncovers significant inter-
connectivity between known and candidate cancer1212 Cell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc.gene products, providing unbiased evidence for an
expanded functional cancer landscape,while demon-
strating how high-quality interactome models will
help ‘‘connect the dots’’ of the genomic revolution.
INTRODUCTION
Since the release of a high-quality human genome sequence a
decade ago (International Human Genome Sequencing Con-
sortium, 2004), our ability to assign genotypes to phenotypes
has exploded.Genes havebeen identified formostMendelian dis-
orders (Hamosh et al., 2005) and over 100,000 alleles have been
implicated in at least one disorder (Stenson et al., 2014). Hundreds
of susceptibility loci have been uncovered for numerous complex
traits (Hindorff et al., 2009) and the genomesof a few thousandhu-
man tumors have been nearly fully sequenced (Chin et al., 2011).
This genomic revolution is poised to generate a complete descrip-
tion of all relevant genotypic variations in the human population.
Genomic sequencing will, however, if performed in isolation,
leave fundamental questions pertaining to genotype-phenotype
relationships unresolved (Vidal et al., 2011). The causal changes
that connect genotype to phenotype remain generally unknown,
especially for complex trait loci and cancer-associated mu-
tations. Evenwhen identified, it is often unclear how a causal mu-
tation perturbs the function of the corresponding gene or gene
product. To ‘‘connect the dots’’ of the genomic revolution, func-
tions and context must be assigned to large numbers of geno-
typic changes.
Complex cellular systems formed by interactions among genes
and gene products, or interactome networks, appear to underlie
most cellular functions (Vidal et al., 2011). Thus, a full understand-
ing of genotype-phenotype relationships in human will require
mechanistic descriptions of how interactome networks are per-
turbed as a result of inherited and somatic disease susceptibil-
ities. This, in turn, will require high-quality and extensive genome
and proteome-scale maps of macromolecular interactions such
as protein-protein interactions (PPIs), protein-nucleic acid inter-
actions, and posttranslational modifiers and their targets.
First-generation human binary PPI interactome maps (Rual
et al., 2005; Stelzl et al., 2005) have already provided network-
based explanations for some genotype-phenotype relation-
ships, but they remain incomplete and of insufficient quality to
derive accurate global interpretations (Figure S1A available on-
line). There is a dire need for empirically-controlled (Venkatesan
et al., 2009) high-quality proteome-scale interactome reference
maps, reminiscent of the high-quality reference genome
sequence that revolutionized human genetics.
The challenges are manifold. Even considering only one splice
variant per gene, approximately 20,000 protein-coding genes
(Kim et al., 2014; Wilhelm et al., 2014) must be handled and
200million protein pairs tested to generate a comprehensive bi-
nary reference PPI map. Whether such a comprehensive network
could ever be mapped by the collective efforts of small-scale
studies remains uncertain. Computational predictions of protein
interactions can generate information at proteome scale (Zhang
et al., 2012) but are inherently limited by biases in currently avail-
able knowledge used to infer such interactomemodels. Should in-
teractomemaps be generated for all individual human tissues us-
ing biochemical cocomplex association data, or would ‘‘context-
free’’ information on direct binary biophysical interaction for all
possible PPIs be preferable? To what extent would these ap-
proaches be complementary? Even with nearly complete, high-
quality reference interactome maps of biophysical interactions,
how can the biological relevance of each interaction be evaluated
under physiological conditions? Here, we begin to address these
questions by generating a proteome-scale map of the human bi-
nary interactome and comparing it to alternative network maps.
RESULTS
Vast Uncharted Interactome Zone in Literature
To investigate whether small-scale studies described in the liter-
ature are adequate to qualitatively and comprehensively map the
human binary PPI network, we assembled all binary pairs identi-
fied in such studies and available as of 2013 from seven public
databases (Figure S1B, see Extended Experimental Procedures,CSection 1). Out of the 33,000 literature binary pairs extracted, two
thirds were reported in only a single publication and detected by
only a single method (Lit-BS pairs), thus potentially presenting
higher rates of curation errors than binary pairs supported bymul-
tiple pieces of evidence (Lit-BMpairs; Tables S1A, S1B, andS1C)
(Cusick et al., 2009). Testing representative samples from both of
these sets using the mammalian protein-protein interaction trap
(MAPPIT) (Eyckerman et al., 2001) and yeast two-hybrid (Y2H)
(Dreze et al., 2010) assays, we observed that Lit-BS pairs were
recovered at rates that were only slightly higher than the ran-
domly selected protein pairs used as negative control (random
reference set; RRS) and significantly lower than Lit-BMpairs (Fig-
ure 1A and Table S2A; see Extended Experimental Procedures,
Section 2). Lit-BS pairs co-occurred in the literature significantly
less often than Lit-BM pairs as indicated by STRING literature
mining scores (Figure 1A and Figure S1C; see Extended Experi-
mental Procedures, Section 2) (von Mering et al., 2003), suggest-
ing that these pairs were less thoroughly studied. Therefore, use
of binary PPI information from public databases should be
restricted to interactions with multiple pieces of evidence in the
literature. In 2013, this corresponded to 11,045 high-quality pro-
tein pairs (Lit-BM-13), more than an order of magnitude below
current estimates of the number of PPIs in the full human interac-
tome (Stumpf et al., 2008; Venkatesan et al., 2009).
The relatively low number of high-quality binary literature PPIs
may reflect inspection biases inherent to small-scale studies.
Some genes such as RB1 are described in hundreds of publi-
cations while most have been mentioned only in a few (e.g.,
the unannotated C11orf21 gene). To investigate the effect of
such biases on the current coverage of the human interactome
network, we organized the interactome search space by ranking
proteins according to the number of publications in which they
are mentioned (Figure 1B). Interactions between highly studied
proteins formed a striking ‘‘dense zone’’ in contrast to a large
sparsely populated zone, or ‘‘sparse zone,’’ involving poorly
studied proteins. Candidate gene products identified in
genome-wide association studies (GWAS) or associated with
Mendelian disorders distribute homogeneously across the pub-
lication-ranked interactome space (Figure 1B and Figure S1D),
demonstrating a need for unbiased systematic PPI mapping to
cover this uncharted territory.
A Proteome-wide Binary Interactome Map
Based on literature-curated information, the human interactome
appears to be restricted to a narrow dense zone, suggesting that
half of the human proteome participates only rarely in the inter-
actome network. Alternatively, the zone that appears sparse in
the literature could actually be homogeneously populated by
PPIs that have been overlooked due to sociological or experi-
mental biases.
To distinguish between these possibilities and address other
fundamental questions outlined above, we generated a new pro-
teome-scale binary interaction map. By acting on all four param-
eters of our empirically-controlled framework (Venkatesan et al.,
2009), we increased the coverage of the human binary interac-
tome with respect to our previous human interactome data set
obtained by investigating a search space defined by7,000 pro-
tein-coding genes (‘‘Space I’’) and published in 2005 (HI-I-05)ell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc. 1213
AB
C
D
Figure 1. Vast Uncharted Interactome Zone in Literature and Generation of a Systematic Binary Data Set
(A) Validation of binary literature pairs extracted from public databases (Bader et al., 2003; Berman et al., 2000; Chatr-Aryamontri et al., 2013; Kerrien et al., 2012;
Licata et al., 2012; Keshava Prasad et al., 2009; Salwinski et al., 2004). Fraction of pairs recovered byMAPPIT at increasing RRS recovery rates (top left) and at 1%
RRS recovery rate (bottom left), found to co-occur in the literature as reported in the STRING database (upper right), and recovered by Y2H (lower right). Shading
and error bars indicate standard error of the proportion. p values, two-sided Fisher’s exact tests. For n values, see Table S6.
(B) Adjacency matrix showing Lit-BM-13 interactions, with proteins in bins of 350 and ordered by number of publications along both axes. Upper and right
histograms show the median number of publications per bin. The color intensity of each square reflects the total number of interactions between proteins for the
corresponding bins. Total number of interactions per bin (lower histogram). Number of products from GWAS loci (Hindorff et al., 2009), Mendelian disease
(Hamosh et al., 2005), and Sanger Cancer Gene Census (Cancer Census) (Futreal et al., 2004) genes per bin (circles).
(legend continued on next page)
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(Rual et al., 2005) (Figures 1C and 1D; see Extended Experi-
mental Procedures, Section 3). A search space consisting of all
pairwise combinations of proteins encoded by 13,000 genes
(‘‘Space II’’; Table S2B) was systematically probed, representing
a 3.1-fold increase with respect to the HI-I-05 search space. To
gain in sensitivity, we performed the Y2H assay in different strain
backgrounds that showed increased detection of pairs of a pos-
itive reference set (PRS) composed of high-quality pairs from the
literature without increasing the detection rate of RRS pairs. To
increase our sampling, the entire search space was screened
twice independently. Pairs identified in this first pass were sub-
sequently tested pairwise in quadruplicate starting from fresh
yeast colonies. To ensure reproducibility, only pairs testing pos-
itive at least three times out of the four attempts and with
confirmed identity were considered interacting pairs, resulting
in 14,000 distinct interacting protein pairs.
We validated these binary interactions using three binary pro-
tein interaction assays that rely on different sets of conditions
than the Y2Hassay: (1) reconstituting amembrane-bound recep-
tor complex in mammalian cells using MAPPIT, (2) in vitro using
the well-based nucleic acid programmable protein array
(wNAPPA) assay (Braun et al., 2009; Ramachandran et al.,
2008), and (3) reconstituting a fluorescent protein in Chinese
hamster ovary cells using a protein-fragment complementation
assay (PCA) (Nyfeler et al., 2005) (see Extended Experimental
Procedures, Section 4). The Y2H pairs exhibited validation rates
that were statistically indistinguishable from a PRS of 500 Lit-
BM interactions while significantly different from an RRS of
700pairswith all threeorthogonal assays andover a large range
of score thresholds (Figure 1D, Tables S2A and S2C), demon-
strating the quality of the entire data set. Using three-dimensional
cocrystal structures available for protein complexes in theProtein
Data Bank (Berman et al., 2000) and for domain-domain interac-
tions (Stein et al., 2011) (FigureS2 andTablesS2D, S2E, andS2F;
see Extended Experimental Procedures, Sections 5 and 6), we
also demonstrated that our binary interactions reflect direct bio-
physical contacts, a conclusion in stark contrast to a previous
report suggesting that Y2H interactions are inconsistent with
structural data (Edwards et al., 2002). Our results also suggested
that Y2Hsensitivity correlateswith the number of residue-residue
contacts and thus presumably with interaction affinity. The
corresponding human interactome data set covering Space II
and reported in 2014 (HI-II-14; Table S2G) is the largest experi-
mentally-determined binary interaction map yet reported, with
13,944 interactions among 4,303 distinct proteins.
Overall Biological Significance
To assess the overall functional relevance of HI-II-14, we
combined computational analyses with a large-scale experi-(C) Improvements from first-generation to second-generation interactome map
Completeness: fraction of all pairwise protein combinations tested; Assay sen
given assay; Sampling sensitivity: fraction of identifiable interactions that are d
positives. PRS: positive reference set; RRS: random reference set.
(D) Experimental pipeline for identifying high-quality binary protein-protein interac
(right) recovered by MAPPIT, PCA, and wNAPPA at increasing assay stringency. S
comparing PRS and HI-II-14 at 1% RRS, two-sided Fisher’s exact tests. For n v
See also Figures S1 and S2 and Tables S1 and S2.
Cmental approach. We first measured enrichment for shared
Gene Ontology (GO) terms and phenotypic annotations and
observed that HI-II-14 shows significant enrichments that are
similar to those of Lit-BM-13 (Figures 2A and 2B; see Extended
Experimental Procedures, Section 7). Second, we measured
how much binary interactions from HI-II-14 reflect membership
in larger protein complexes as annotated in CORUM (Ruepp
et al., 2010) or reported in a cocomplex association map
(Woodsmith and Stelzl, 2014). In both cases, we observed a
significant enrichment for binary interactions between protein
pairs that belong to a common complex (p < 0.001; Figure 2B).
Third, we performed a similar analysis using tissue-specific
mRNA expression data across the 16 human tissues of the Illu-
mina Human Body Map 2.0 project as well as cellular compart-
ment localization annotations from the GO Slim terms. Again,
HI-II-14 was enriched for interactions mediated by protein pairs
present in at least one common compartment or cell type (Fig-
ures 2C and 2D). Finally, we measured the overlap of HI-II-14
with specific biochemical relationships, as represented by
kinase-substrate interactions. Both HI-II-14 and Lit-BM-13
contained significantly more PPIs reflecting known kinase-
substrate relationships (Hornbeck et al., 2012) than the corre-
sponding degree-controlled randomized networks (Figure 2E).
In addition, HI-II-14 tended to connect tyrosine and serine/
threonine kinases (Manning et al., 2002) to proteins with tyro-
sine or serine/threonine phospho-sites (Hornbeck et al., 2012;
Olsen et al., 2010), respectively (Figure S3A), pointing to
the corresponding interactions being genuine kinase-sub-
strate interactions. In short, our systematic interactome map,
which was generated independently from any pre-existing
biological information, reveals functional relationships at
levels comparable to those seen for the literature-based
interaction map.
To further investigate the overall biological relevance of HI-II-
14, we used an experimental approach that compares the
impact of mutations associated with human disorders to that
of common variants with no reported phenotypic consequences
on biophysical interactions (Figure 3). Our rationale is that a set of
interactions corresponding to genuine functional relationships
should more likely be perturbed by disease-associated mu-
tations than by common variants. The following example will
illustrate this concept. Mutations R24C and R24H in CDK4 are
clearly associated with melanoma by conferring resistance to
CDKN2A inhibition (Wo¨lfel et al., 1995), whereas N41S and
S52N mutations are of less clear clinical significance (Zhong
et al., 2009) and have remained functionally uncharacterized.
HI-II-14 contains five CDK4 interactors: two inhibitors (CDKN2C
and CDKN2D), two cyclins (CCND1 and CCND3), and HOOK1, a
novel interacting partner and a potential phosphorylation targetping based on an empirically-controlled framework (Venkatesan et al., 2009).
sitivity: fraction of all true biophysical interactions that are identifiable by a
etected in the experiment; Precision: fraction of reported pairs that are true
tions (left). ORF: open reading frame. Fraction of HI-II-14, PRS, and RRS pairs
hading indicates standard error of the proportion. p > 0.05 for all assays when
alues, see Table S6.
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Figure 2. Overall Biological Significance
(A) Schematic of the method to assess biological
relevance of binary maps.
(B) Enrichment of binary interactome maps for
functional relationships (left) and cocomplex
memberships (right). Error bars indicate 95%
confidence intervals. BP: Biological process; MF:
Molecular function; CC: Cellular component.
Mouse phenotypes: Shared phenotypes in mouse
models by orthology mapping. MS: Mass-spec-
trometry-basedmap. Enrichments: p% 0.05 for all
annotations and maps, two-sided Fisher’s exact
tests. For n values, see Table S6.
(C) and (D) Fraction of binary interactions between
proteins localized in a common cellular compart-
ment and proteins copresent in at least one cell
type (arrows) compared to those in 1,000 degree-
controlled randomized networks. Empirical p
values. For n values, see Table S6.
(E) Number of known kinase-substrate interactions
found in binary maps (arrows) compared to those
in 1,000 randomized networks. Empirical p values
are shown.
See also Figure S3.of CDK4 (Figure S3B). In agreement with previous reports, the
comparative interaction profile shows that R24C and R24H,
but not N41S and S52N, specifically perturb CDK4 binding to
CDKN2C (Figure 3).
In total, we identified 32 human genes for which: (1) the cor-
responding gene product is reported to have binary interactors
in HI-II-14, (2) germline disease-associated missense mutations
have been reported, and (3) common coding missense variants
unlikely to be involved in any disease have been identified in the
1000 Genomes Project (1000 Genomes Project Consortium,
2012). To avoid overrepresentation of certain genes, we sele-
cted a total of 115 variants, testing up to four disease and
four common variants per disease gene for their impact on
the ability of the corresponding proteins to interact with known
interaction partners (see Extended Experimental Procedures,
Section 8). Disease variants were 10-fold more likely to perturb
interactions than nondisease variants (Figure 3 and Table S3).
Strikingly, more than 55% of the 107 HI-II-14 interactions tested
were perturbed by at least one disease-associated variant, and
the same trend was observed when considering only mutants
with evidence of expression in yeast as indicated by their ability
to mediate at least one interaction (Figure S3C). Examples of
novel specifically perturbed interactions include AANAT-1216 Cell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc.BHLHE40 and RAD51D-IKZF1 (Figure 3).
In the first case, the A129T mutation in
AANAT is known to be associated with
a delayed sleeping phase syndrome
and specifically perturbs an interaction
between AANAT and BHLHE40, the
product of a gene reported to function
in circadian rhythm regulation (Naka-
shima et al., 2008). In the second case,
the breast-cancer-associated RAD51D
E233G mutation perturbs interactionswith a number of partners, including the known cancer gene
product IKZF1 (Futreal et al., 2004).
Altogether these computational and experimental results pro-
vide strong evidence that HI-II-14 pairs correspond to biologi-
cally relevant interactions and represent a valuable resource to
further our understanding of the human interactome and its per-
turbations in human disease.
A ‘‘Broader’’ Interactome
Unlike literature-curated interactions, HI-II-14 protein pairs are
distributed homogeneously across the interactome space (Fig-
ure 4A), indicating that sociological biases, and not fundamental
biological properties, underlie the existence of a densely popu-
lated zone in the literature. Since 1994, the number of high-qual-
ity binary literature PPIs has grown roughly linearly to reach
11,000 interactions in 2013 (Figure 4B), while systematic data
sets are punctuated by a few large-scale releases. Although
the sparse territory of the literature map gradually gets popu-
lated, interaction density in this zone continues to lag behind
that of the dense zone (Figure 4B). In terms of proteome
coverage, the expansion rate is faster for systematic maps
than for literature maps, especially in the sparse territory (Fig-
ure 4C and Figure S4A; see Extended Experimental Procedures,
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See also Figure S3 and Table S3.Section 9). While Lit-BM-13 provides more information in the
dense zone, HI-II-14 reveals interactions for more than 2,000
proteins absent from Lit-BM-13. These observations are likely
due to a tendency of the literature map to expand from already
connected proteins (Figure 4D).CTo more deeply explore the heterogeneous coverage of the
human interactome, we compared HI-II-14 and Lit-BM-13 to a
collection of 25,000 predicted binary PPIs of high-confidence
(PrePPI-HC) (Zhang et al., 2012) and a co-fractionation map of
14,000 potentially binary interactions (Co-Frac) (Havugimanaell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc. 1217
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(A) Adjacency matrices showing Lit-BM-13 (blue) and HI-II-14 (purple) interactions, with proteins in bins of 350 and ordered by number of publications along
both axes. The color intensity of each square reflects the total number of interactions for the corresponding bins.
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of systematic binary data sets or date of publication that resulted in inclusion of interactions in Lit-BM-13. Adjacency matrices (bottom) as in Figure 4A.
(C) Fraction of the human proteome present in binary interactome maps at selected time points since 1994, considering the full interactome space (left) or only
dense (middle) and sparse (right) zones of Lit-BM-13 with respect to number of publications.
(D) Fraction of new interactions connecting two proteins that were both absent from the map at the previous time point (four years interval; middle) compared to
the average in 1,000 randomized networks (right). Error bars indicate standard deviation.et al., 2012). We tested the extent to which these two data sets
contain binary interactions (see Extended Experimental Proce-
dures, Section 10). Representative samples from both Co-Frac
and PrePPI-HC were recovered by Y2H at a much lower rate
than a sample of Lit-BM-13 and appeared statistically indi-1218 Cell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc.stinguishable from random pairs (Figure 5A and Table S4A). A
literature non-binary data set (Lit-NB-13) performed similarly.
However, Co-Frac and PrePPI-HC, like Lit-NB-13, were both
significantly enriched for functionally relevant relationships.
Thus, although these data sets represent potentially valuable
resources, both Co-Frac and PrePPI-HC appear to be more
comparable to nonbinary than to binary data sets. Surprisingly,
even though PrePPI-HC and Co-Frac systematically surveyed
the full human proteome and map different portions of the inter-
actome (Figures S4B), both exhibit a strong tendency to report
interactions among well-studied proteins (Figure 5B). This bias
is likely due to the integration of functional annotations in the
generation of both data sets.
Because coverage might depend on gene expression levels,
we also examined interactome maps for expression-related
sparse versus dense zones. Co-Frac shows a strong bias toward
interactions involving proteins encoded by genes highly ex-
pressed in the cell lines used (Figure 5B). This expression-depen-
dent bias is echoed in the literature map, perhaps reflecting a
general tendency to study highly expressed proteins. In contrast,
both HI-II-14 and PrePPI-HC exhibit a uniform interaction density
across the full spectrum of expression levels, likely explained by
the standardized expression of proteins tested in Y2H and by the
independence of homology-based predictions from expression
levels.
We more broadly explored the intrinsic biases that might influ-
ence the appearance of sparsely populated zones by examining
21 protein or gene properties, roughly classified as expression-,
sequence-, or knowledge-based (Figures 5B and 5C, Tables S4B
and S4C; see Extended Experimental Procedures, Section 9).
For example, PrePPI-HC is virtually devoid of interactions be-
tween proteins lacking Pfamdomains, consistent with conserved
domains forming the basis of the prediction method. HI-II-14
appears depleted of interactions among proteins containing pre-
dicted transmembrane helices, consistent with expected limita-
tions of the Y2H assay (Stagljar and Fields, 2002). Co-Frac is
similarly depleted in interactions involving proteins with trans-
membrane helices, which may result from membrane-bound
proteins being filtered out during biochemical fractionations.
Compared to HI-II-14, HI-I-05 presented a less homogenous
coverage of the space with respect to abundance and knowl-
edge properties, likely reflecting the content of early versions
of the hORFeome (Figure S4C). Importantly, no single map
appeared unbiased in all 21 examined properties. A combined
map presented a slightly increased homogeneity although
intrinsic knowledge biases of the three maps using literature-
derived evidence were still predominant.
To confirm that HI-II-14 interactions found in the sparse zones
of the three other maps are of as high quality as those found in
dense zones, we compared MAPPIT validation rates and func-
tional enrichment across these zones for all protein properties
examined. MAPPIT validation rates of dense and sparse zone
pairs were consistent for nearly all properties (Figures 5D and
S4D), indicating thatHI-II-14 interactions areof similar biophysical
quality throughout the full interactome space. Functional enrich-
ment within the sparse zone was statistically indistinguishable
from that of the dense zone (Figures 5D and S4E), demonstrating
the functional importance of HI-II-14 biophysical interactions in
zones covered sparsely by other types of interactome maps.
Considering all current maps, more than half of the proteome
is now known to participate in the interactome network. Our sys-
tematic exploration of previously uncharted territories dramati-
cally expands the interactome landscape, suggesting that theChuman interactome network is broader in scope than previously
observed and that the entire proteome may be represented
within a fully mapped interactome.
Interactome Network and Cancer Landscape
Genes associated with the same disease are believed to be
preferentially interconnected in interactome networks (Baraba´si
et al., 2011; Vidal et al., 2011). However, in many cases, these
observations were made with interactome maps that are
composites of diverse evidence, e.g., binary PPIs, cocomplex
memberships, and functional associations, a situation further
complicated by the uneven quality and sociological biases
described above. Using HI-II-14, we revisited this concept for
cancer gene products. Our goal was to investigate whether the
cancer genomic landscape is limited to the known cancer genes
curated in the Sanger Cancer Gene Census (‘‘Cancer Census’’)
(Futreal et al., 2004), or if, alternatively, it might extend to some
of the hundreds of additional candidate genes enriched in so-
matic mutations uncovered by systematic cancer genome
sequencing (‘‘SM genes’’) (Chin et al., 2011) and/or identified
by functional genomic strategies such as Sleeping Beauty trans-
poson-based screens in mice (‘‘SB genes’’) (Copeland and Jen-
kins, 2010) or global investigations on DNA tumor virus targets
(‘‘VT genes’’) (Rozenblatt-Rosen et al., 2012).
Given our homogeneous coverage of the space for known
(Cancer Census) and candidate (SB, SM, and VT) cancer genes
(Figure 6A), we first tested the postulated central role of cancer
gene products in biological networks (Baraba´si et al., 2011) and
verified that both sets tend to have more interactions and to be
more central in the systematic map than proteins not associ-
ated with cancer (Figure 6B). We then examined the intercon-
nectivity of known cancer proteins and showed that Cancer
Census gene products interact with each other more frequently
than expected by chance, a trend not apparent in HI-I-05 (Fig-
ure 6C). We sought to use this topological property as the basis
for novel cancer gene discovery in the large lists of cancer can-
didates from genomic and functional genomic screens.
We examined whether products of candidate cancer genes
identified by GWAS (Table S5A) tend to be connected to Cancer
Census proteins, and observed significant connectivity in all four
maps (Figure S5A; see Extended Experimental Procedures, Sec-
tion 11). When loci containing a known cancer gene were
excluded, only HI-II-14 showed such connectivity, supporting
its unique value to identify cancer candidate genes beyond those
already well demonstrated (Figures 7A and S5A). In further
support of their association with cancer, genes in cancer
GWAS loci prioritized by ‘‘guilt-by-association’’ in HI-II-14 tend
to correspond to cancer candidates from systematic cancer
studies (Figures 7B and 7C). These results suggest that can-
cer-associated proteins tend to form subnetworks perturbed in
tumorigenesis, and that HI-II-14 provides new context to priori-
tize cancer genes from genome-wide studies.
The following example illustrates the power of our combined
approach. C-terminal Binding Protein 2 (CTBP2) is encoded
at a locus associated with prostate cancer susceptibility
(Thomas et al., 2008) and belongs to both SB and VT gene lists
(Mann et al., 2012; Rozenblatt-Rosen et al., 2012). Two Cancer
Census genes, IKZF1 and FLI1, encode interacting partners ofell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc. 1219
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Figure 5. Comparison of Interaction Mapping Approaches
(A) Evaluation of the quality of Co-Frac (orange), PrePPI-HC (red), and pairs from small-scale experiments in the literature with no binary evidence (Lit-NB-13,
grey). Fraction of pairs recovered by Y2H as compared to pairs from Lit-BM-13 and pairs of randomly selected proteins (RRS) (left). Error bars indicate standard
error of the proportion. Enrichment in functional interactions and cocomplex memberships (right). Legend as in Figure 2B. For n values, see Table S6.
(B) Adjacency matrices for HI-II-14, Lit-BM-13, Co-Frac, and PrePPI-HC maps, with proteins per bins of 350 and ordered by number of publications, mRNA
abundance in HEK cells, fraction of protein sequence covered by Pfam domains, or fraction of protein sequence in transmembrane helices. Figure legend as in
Figure 1B.
(C) Highest interaction density imbalances (observed minus expected) in the four maps, the union of all four maps, and our previous binary map (HI-I-05) for 21
protein properties.
(legend continued on next page)
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CTBP2 in HI-II-14. These are transcription factors with tumor
suppressor (Payne and Dovat, 2011) and proto-oncogene (Korn-
blau et al., 2011) roles, respectively, in lymphoid tumors. Given
its interactions with IKZF1 and FLI1, we investigated the poten-
tial role of CTBP2 in lymphoid tumorigenesis. In the Cancer Cell
Line Encyclopedia (Barretina et al., 2012), FLI1 was significantly
more often amplified in lymphoid than in other cell lines (Fig-
ure 7D), consistent with its proposed proto-oncogenic role in
these tumors. In contrast, both CTBP2 and IKZF1, but not
CTBP1, were deleted significantly more often in lymphoid cancer
cell lines. Notably, deletion of CTBP2 or IKZF1 and amplification
of FLI1 were mostly nonoverlapping in the different cell lines,
suggesting that either event may be sufficient to affect tumori-
genesis (Figure S5B). Altogether, these results suggest a role
for CTBP2 in suppressing lymphoid tumors by direct repression
of FLI1 function, potentially involving IKZF1.
Finally, we assessed how HI-II-14 interactions can be inte-
grated with genomic and functional genomic data sets. Going
beyond the ‘‘guilt-by-profiling’’ concept, we also used these
gene sets in ‘‘guilt-by-association’’ predictions in a combined
model (Figure S6A), which leads to substantially improved can-
cer gene rankings over those found using either predictive strat-
egy alone (Figures 7E, S6B, and S6C and Table S5B; see
Extended Experimental Procedures, Section 12). In contrast, a
similar analysis using HI-I-05 interactions showed that its limited
size prevented inclusion of any guilt-by-association terms
(Figure S6D). Genes significantly mutated in cancer patients
from recent TCGA pan-cancer mutation screens (Table S5C)
(Lawrence et al., 2014) were enriched among highly ranked pre-
dictions from the combined model (p = 63 103, one-sided Wil-
coxon rank test), supporting the validity of our integrated cancer
gene predictions. Our top-ranked prediction was the cyclin-
dependent kinase 4 (CDK4), a well-known cancer gene product.
Four other genes from the Cancer Census list appeared among
the top 25 ranked genes. Strikingly, STAT3, which ranked third,
was added to the Cancer Census after our training set was es-
tablished, highlighting the ability of this approach to identify
novel cancer gene products.
To characterize the biological processes in which the candi-
date cancer genes predicted by the combined model are likely
to be involved, we identified binary interactions linking them to
each other or to Cancer Census proteins in the 12 ‘‘pathways
of cancer’’ relevant to cancer development and progression
(Table S5D) (Vogelstein et al., 2013). Of our top 100 candidates,
60 mapped to at least one cancer pathway (Figures 7F and S7),
twice as many as would be expected from predictions using
either the guilt-by-profiling or guilt-by-association approach
alone.Wepropose thatmanynovel cancer candidates canbean-
notated to specific processes based on their interactions with
CancerCensus geneproducts andknownparticipation in cellular
pathways. For example, the candidate protein ID3, a DNA-bind-
ing inhibitor, interacts with the two Cancer Census transcription(D) Precision at 1%RRS recovery in theMAPPIT assay (top, error bars indicate sta
Ontology and mouse phenotypes based annotations, error bars indicate 95% co
from Lit-BM-13, Co-Frac, and PrePPI-HC. p > 0.05 for all pairwise comparisons
Table S6.
See also Figure S4 and Table S4.
Cfactors TCF12 and TCF3, suggesting a role for ID3 in the regula-
tion of transcription by inhibiting binding of specific transcription
factors to DNA (Loveys et al., 1996; Richter et al., 2012). CTBP2,
whichwe identified as apotential suppressor in lymphoid tumors,
represents another example (Figures 5E and S7).
In summary, the increased and uniform coverage of HI-II-14
demonstrates that known and candidate cancer gene products
are highly connected in the interactome network, which in turn
provides unbiased evidence for an expanded functional cancer
landscape.DISCUSSION
By systematically screening half of the interactome space with
minimal inspection bias, we more than doubled the number of
high-quality binary PPIs available from the literature. Covering
zones of the human interactome landscape that have been
weakly charted by other approaches, our systematic binary
map provides deeper functional context to thousands of pro-
teins, as demonstrated for candidates identified in unbiased
cancer genomic screens. Systematic binary mapping therefore
stands as a powerful approach to ‘‘connect the dots’’ of the
genomic revolution.
Combining high-quality binary pairs from the literature with
systematic binary maps, 30,000 high-confidence interactions
are now available. It is likely that a large proportion of the human
interactome can soon be mapped by taking advantage of the
emergence of reference proteome maps (Kim et al., 2014;
Wilhelm et al., 2014), a combination of nearly complete clone col-
lections (Yang et al., 2011), rapid improvements in Y2H assay
sensitivity, and emerging interaction-mapping technologies
that drastically reduce cost (Caufield et al., 2012; Stagljar and
Fields, 2002; Yu et al., 2011).
Reference binary interactome maps of increased coverage
and quality will be required to interpret condition-specific inter-
actions and to characterize the effects of splicing and genetic
variation on interactions (Zhong et al., 2009). While protein-pro-
tein interactions represent an important class of interactions be-
tweenmacromolecules, future efforts integrating this information
with protein-DNA, protein-RNA, RNA-RNA or protein-metabolite
interactions will provide a unified view of the molecular inter-
actions governing cell behavior. Just as a reference genome
enabled detailed maps of human genetic variation (1000 Ge-
nomes Project Consortium, 2012), completion of a reference
interactome network map will enable deeper insight into geno-
type-phenotype relationships in human.EXPERIMENTAL PROCEDURES
Extraction of the Literature-Based Data Sets
Human PPIs annotated with tractable publication records were extracted from
seven databases through August 2013. Large-scale systematic data sets andndard error of the proportion) and functional enrichment (bottom, union of Gene
nfidence intervals) of HI-II-14 pairs found in dense and sparse zones mirrored
of dense and sparse zones, two-sided Fisher’s exact tests. For n values, see
ell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc. 1221
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Figure 6. Network Properties of Cancer
Gene Products
(A) Adjacency matrices for Lit-BM-13 and HI-II-14
only showing interactions involving the product of
a Cancer Census (Futreal et al., 2004) or of a
candidate cancer gene. Figure legend as in Fig-
ure 1B. Lower histograms show for each bin, the
fraction of cancer candidates having at least one
interaction.
(B) Distribution of the number of interactions (de-
gree) and normalized number of shortest paths
between proteins (betweenness centrality) for
products of Cancer Census and of candidate
cancer genes in Lit-BM-13 and in HI-II-14 maps as
compared to other proteins (right; * for p < 0.05, NS
for p > 0.05, two-sided Wilcoxon rank sum tests).
For n values, see Table S6.
(C) Number of interactions between products of
Cancer Census genes (arrows) in HI-I-05, HI-II-14,
Lit-BM as of 2000 (Lit-BM-00) and as of 2013 (Lit-
BM-13), as compared to 1,000 degree-controlled
randomized networks. Empirical p values. For n
values, see Table S6.pairs involving products of UBC, SUMO1, SUMO2, SUMO3, SUMO4, or
NEDD8, were excluded. The remaining pairs were divided into those having
no pieces of binary evidence (Lit-NB) and those with at least one piece of bi-
nary evidence based on PSI-MI experimental method codes. Binary pairs
were divided between pairs with one and with two or more pieces of evidence
(Lit-BS and Lit-BM, respectively). For benchmark experiments in Y2H,
MAPPIT, PCA, and wNAPPA, equivalent data sets were extracted similarly
in December 2010.1222 Cell 159, 1212–1226, November 20, 2014 ª2014 Elsevier Inc.Generation of the Binary Protein-Protein
Interaction Map
HI-II-14 was generated by screening all pairwise
combinations of 15,517 ORFs from hORFeome
v5.1 (Space II) as described previously (Dreze
et al., 2010). ORFs encoding first pass pairs were
identified either by Sanger sequencing or by
Stitch-seq (Yu et al., 2011). HI-II-14 was validated
by comparing a subset of 809 interactions to a
positive and a random reference set of 460 and
698 protein pairs, respectively, using MAPPIT,
PCA, and wNAPPA assays.
Interaction Perturbation by Missense
Mutations
Disease variants were obtained from the Human
GeneMutationDatabase (HGMD2009V2) (Stenson
etal., 2014) andcommonvariantswerederived from
the 1000 Genomes Project (1000 Genomes Project
Consortium, 2012). Only variants with a minor allele
frequency above 1%were considered common. All
successfully cloned disease and common variants
were systematically tested for interaction with all in-
teractors of their wild-type counterpart.
Interaction Density Imbalance
For each protein property, we ranked all proteins
and, for any property threshold, partitioned the in-
teractome space into a first region containing pairs
of proteins both above (or below) the threshold,
and a second region containing all remaining pairs.
Interaction density imbalance of a given map for agiven threshold was calculated as the fraction of PPIs observed in the first re-
gion minus the fraction of PPIs expected assuming a uniform distribution in the
space. Dense and sparse zones were defined by identifying the threshold for
which the deviation from expectation is maximal.
Measure of Functional Enrichment
For each pairwise comparison, PPI and functional maps were trimmed to pairs
where both proteins were present in both maps and restricted to Space II to
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allow comparison between PPI maps. Functional enrichment odds ratios were
calculated using Fisher’s exact tests.
GWAS Analysis
307 distinct cancer-associated SNPs were identified from 75 GWAS publica-
tions covering 10 types of cancer and 142 distinct loci were identified at a link-
age disequilibrium threshold of 0.9. For each map, we calculated the number
of loci encoding an interactor of a Cancer Census protein over the number of
loci encoding a protein in the PPI map. To assess significance, we measured
the corresponding fraction when randomly selecting for each locus the same
number of proteins than genes with products in the PPI map.
Cancer Association Scoring System
For each gene, seven features were measured. Three features represent
membership in the SB, SM, and VT lists of candidate cancer genes (‘‘guilt-
by-profiling’’ features). The four other features represent its number of interac-
tors in HI-II-14 that are present in these three lists and in the Cancer Census
list, normalized by the expected numbers in degree-controlled randomized
networks (‘‘guilt-by-association’’ features). We measured the ability of each
feature to prioritize known Cancer Census genes with separate logistic regres-
sion models. We combined all seven features in a forward stepwise logistic
regression model using the Akaike information criterion to determine the
stepwise halting. The final set of features selected was: the SB, SM, and VT
guilt-by-profiling and the Cancer Census and SB guilt-by-association features.
‘‘Receiver Operating Characteristic’’ curves were obtained by measuring at
decreasing score threshold the fraction of knownCancer Census genes recov-
ered and the corresponding fraction of proteins predicted as candidate cancer
genes.
Data Sets
For reference data sets used in this study, see Extended Experimental Proce-
dures, Section 13. All high-quality binary PPIs described in this paper can be
accessed at: http://interactome.dfci.harvard.edu/H_sapiens/.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2014.10.050.
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